{"result": {"id": "cf32eb1b-ca09-403c-90a8-748640302365", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>ACEI<|>ORGANIZATION<|>Angiotensin-converting enzyme inhibitors, a class of drugs used in hypertension treatment\")  \n##\n(\"entity\"<|>ARB<|>ORGANIZATION<|>Angiotensin receptor blockers, a class of drugs used in hypertension treatment\")  \n##\n(\"entity\"<|>CCB<|>ORGANIZATION<|>Calcium channel blockers, a class of drugs including dihydropyridine types used in hypertension treatment\")  \n##\n(\"entity\"<|>β受体阻滞剂<|>ORGANIZATION<|>Beta blockers, a class of drugs used in hypertension treatment\")  \n##\n(\"entity\"<|>噻嗪类利尿剂<|>ORGANIZATION<|>Thiazide diuretics, a class of drugs used in hypertension treatment\")  \n##\n(\"relationship\"<|>ACEI<|>ARB<|>Both are classes of antihypertensive drugs that act on the renin-angiotensin system<|>7\")  \n##\n(\"relationship\"<|>CCB<|>ARB<|>Commonly combined in hypertension treatment regimens<|>8\")  \n##\n(\"relationship\"<|>CCB<|>ACEI<|>Commonly combined in hypertension treatment regimens<|>8\")  \n##\n(\"relationship\"<|>CCB<|>噻嗪类利尿剂<|>Commonly combined in hypertension treatment regimens<|>8\")  \n##\n(\"relationship\"<|>ARB<|>噻嗪类利尿剂<|>Commonly combined in hypertension treatment regimens<|>8\")  \n##\n(\"relationship\"<|>ACEI<|>噻嗪类利尿剂<|>Commonly combined in hypertension treatment regimens<|>8\")  \n##\n(\"relationship\"<|>CCB<|>β受体阻滞剂<|>Sometimes combined in hypertension treatment, with offsetting side effects<|>6\")  \n##\n(\"relationship\"<|>ARNI<|>ARB<|>ARNI includes ARB effects in its mechanism of action<|>9\")  \n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558640, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 457, "prompt_tokens": 2821, "total_tokens": 3278, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 2752}, "prompt_cache_hit_tokens": 2752, "prompt_cache_miss_tokens": 69}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 为踝  部水肿 ,可被 ACEI或 ARB减轻或抵消 。高血压综合  防治研究(Chinese hypertension intervention efficacy study,CHIEF)[234] 表明 ,小剂量长效二氢吡啶类 CCB+  ARB用于高血压患者初始治疗 ,可明显提高血压控制  率 。③二氢吡啶类 CCB+噻嗪类利尿剂 , FEVER研  究证实 ,二氢吡啶类 CCB+噻嗪类利尿剂治疗 ,可降  低高血 压 患 者 脑 卒 中 发 生 的 风 险 。 ④二 氢 吡 啶 类  CCB+β受体阻滞剂 ,二氢吡啶类 CCB具有扩张血管  和轻度增加心率的作用 ,可抵消 β受体阻滞剂收缩血  管和减慢心率的作用 。两药联合可使不良反应减轻。\n　　　(4) 多种药物的联合方案 : ①三药联合的方案 ,在 上述两药联合方案中加上另一种降压药便构成三药联 合方案 ,其中二氢吡啶类 CCB+ACEI(或 ARB) +噻 嗪类利尿剂组成的联合方案最为常用 。②四种药联合 的方案 ,主要适用于难治性高血压患者 ,可以在上述三 药联合基础上加用第 4种药物 ,如 β受体阻滞剂、醛固\n\n\n\n酮受体拮抗剂、氨苯蝶啶、可乐定或 α受体阻滞剂等 。  表 18 列 出 了 常 用 降 压 药 的 联 合 方 案 建 议。\nARNI类药物包括了 ARB的作用 , 因此其联合治疗可\n\n\n参照 ARB, 与二氢吡啶类 CCB 或噻嗪类利尿剂 或 β受体阻滞剂进行两药或三药联合治疗。\n\n\n表 18   常用降压药的联合方案建议\n\n主要推荐应用的优化联合治疗方案\t可以考虑使用的联合治疗方案\t不推荐的联合治疗方案\n·二氢吡啶类 CCB+ARB   ·二氢吡啶类 CCB+ACEI  ·二氢吡啶类 CCB+ARNI ·ARB+噻嗪类利尿剂\n·ACEI+噻嗪类利尿剂  ·ARNI+噻嗪类利尿剂\n·二氢吡啶类 CCB+噻嗪类利尿剂 ·二氢吡啶类 CCB+β受体阻滞剂\t·利尿剂 +β受体阻滞剂\n· α受体阻滞剂 +β受体阻滞剂   ·二氢吡啶类 CCB+保钾利尿剂 · 噻嗪类利尿剂 +保钾利尿剂\n·ARB+β受体阻滞剂\n·ACEI+β受体阻滞剂  ·ARNI+β受体阻滞剂\t·ACEI、ARB、ARNI与阿利吉仑这四种药物之间的任意联合 · 中枢作用药 +β受体阻滞剂\n注 :CCB为钙通道阻滞药;ACEI为血管紧张素转换酶抑制药;ARB为血管紧张素受体阻滞药;ARNI为血管紧张素受体脑啡肽酶抑制剂。\n\n\n　　　(5)SPC:是联合降压治疗有效的实现方式 。通常 由不同作用机制的两种或两种以上的降�\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>CHINESE HYPERTENSION INTERVENTION EFFICACY STUDY<|>EVENT<|>A study demonstrating the efficacy of small-dose long-acting dihydropyridine CCB + ARB as initial treatment for hypertension patients, significantly improving blood pressure control rate\")  \n##  \n(\"entity\"<|>FEVER<|>EVENT<|>A study confirming that dihydropyridine CCB + thiazide diuretic treatment can reduce the risk of stroke in hypertension patients\")  \n##  \n(\"entity\"<|>ARNI<|>ORGANIZATION<|>Angiotensin receptor-neprilysin inhibitor, a class of drugs that includes ARB effects and is used in combination therapies for hypertension\")  \n##  \n(\"relationship\"<|>CHINESE HYPERTENSION INTERVENTION EFFICACY STUDY<|>ARNI<|>The CHIEF study involves ARB, which is part of ARNI's drug class, in combination therapies<|>6\")  \n##  \n(\"relationship\"<|>FEVER<|>ARNI<|>The FEVER study involves dihydropyridine CCB, which can be combined with ARNI in hypertension treatment<|>5\")  \n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_f141c49fa06c7629a401118dedf7364f8e922260ec4711e79ea7d280ada91222_v2"}